8 Analysts Assess Altimmune: What You Need To Know
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Cue Biopharma (CUE) and Atricure (ATRC)
Altimmune's Strategic Positioning and Promising Future in Obesity and MASH Treatment Markets
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
Express News | HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
Altimmune's Pemvidutide: A Promising Best-in-Class Therapy With Broad Potential and Strong Buy Rating
